Progression of coronary artery disease in non-ischemic dilated cardiomyopathy

Coronary Artery Disease

Volumn 15, Issue 5, 2004, Pages 291-297

  Hedrich, Olaf ^a   Jacob, Mark ^b   Hauptman, Paul J ^a,c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

Author keywords

Coronary artery disease; Dilated cardiomyopathy; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DIAGNOSTIC ERROR; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; EXERCISE TOLERANCE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FUNCTION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL RATE;

CARDIOMYOPATHY, DILATED; CAUSE OF DEATH; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA;

EID: 4043181291     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mca.0000136186.85058.b8     Document Type: Review

References (79)

1. Massie BM, Shah NB. Evolving trends in epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133:703-712.
2. American Heart Association. Heart disease and stroke statistics - 2003 update. Dallas: American Heart Association; 2002. Available from http://ww.americanheart.org.
3. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-1552.
4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani FE, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310.
5. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 1997; 96:856-863.
6. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
7. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353:2001-2007.
8. Cardiac Insufficiency Bisoprolol Study Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:1765-1773.
9. Cardiac Insufficiency Bisoprolol Study-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 1999; 353:9-13.
10. Packer M, Colucci W, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE Trial. Circulation 1996; 94:2793-2799.
11. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al., for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effects of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-1114.
12. The RESOLVD Investigators. Effects of Metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction study (Clinical investigation and reports). Circulation 2000; 101:378-384.
13. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
14. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587.
15. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
16. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
17. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW, for the Beta-blocker Evaluation of Survival Trial (BEST) Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659-1667.
18. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al., for the Randomized Aldactone Evaluation Study (RALES) Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
19. Garg R, Gorlin R, Smith T, Yusuf S, for the Digitalis Investigation Group (DIG). The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533.
20. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low doses and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100:2312-2318.
21. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS). Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658.
22. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
23. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al., for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339:1810-1816.
24. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al., for the REMATCH Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:1435-1443.
25. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al., for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329:1-7.
26. Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO Study): a randomised double-blind trial. Lancet 2002; 360:196-202.
27. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al., for the OVERTURE Study Group. Comparison of omipatrilat and enalapril in patients with chronic heart failure - the Omipatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106:920-926.
28. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al., for the US Carvedilol Heart Failure Study Group. Congestive heart failure/myocardial disease: carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94:2800-2806.
29. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report - 2001. J Heart Lung Transplant 2001; 20:805-815.
30. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077-1084.
31. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331:1564-1575.
32. Bozkurt B, Mann DL. Dilated cardiomyopathy. In: Willerson JT, Cohn JN (editors): Cardiovascular medicine. 2nd ed. Philadelphia: Churchill Livingstone; 2000. pp. 1048.
33. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JGF, Massie BM, Ryden L. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003; 89:42-48.
34. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340:1173-1178.
35. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Web Site 2001; http://www.acc.org/clinical/guidelines/ failure/hf_index.htm.
36. Konstam M, Dracup K, Baker D, Bottorff MB, Brooks NH, Daley RA, et al. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. Rockville: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services; June 1994. Clinical Practice Guideline No. 11, AHCPR Publication No. 94-0612.
37. Dunn RF, Uren RF, Sadick N, Bautovich G, McLaughlin A, Hiroe M, et al. Comparison of thallium-201 scanning in idiopathic dilated cardiomyopathy and severe coronary artery disease. Circulation 1982; 66:804-810.
38. Glamann DB, Lange RA, Corbett JR, Hillis LD. Utility of various radionuclide techniques for distinguishing ischemic from nonischemic dilated cardiomyopathy. Arch Intern Med 1992; 152:769-772.
39. Regar E, Serruys PW. Ten years after introduction of intravascular ultrasound in the catheterization laboratory: tool or toy? Zeitschr Kardiol 2002; 91 (suppl 3):89-97.
40. Nissen SE. Shortcomings of coronary angiography and their implications in clinical practice. Cleve Clin J Med 1999; 66:479-485.
41. Bortman G, Sellanes M, Odell DS, Ring WS, Olivari M. Discrepancy between pre- and post-transplant diagnosis of end-stage dilated cardiomyopathy. Am J Cardiol 1994; 74:921-924.
42. Perna ER, Macin SM, Parras JI, Pantich R, Farias EF, Badaracco JR, et al. Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 2002; 143:814-820.
43. La Vecchia L, Mezzena G, Ometto R, Finocchi G, Bedogni F, Soffiati G, et al. Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am J Cardiol 1997; 80:88-90.
44. Unverferth DV, Magorien RD, Lewis RP, Leier CV. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 1983; 105:176-179.
45. Narang R, Cleland JGF, Erhardt L, Ball SG, Coats AJ, Cowley AJ, et al. Mode of death in chronic heart failure: a request and proposition for more accurate classification. Eur Heart J 1996; 17:1390-1403.
46. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985; 72:681-685.
47. Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 1992; 85(suppl):I50-I56.
48. Cleland JGF, Massie B, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999; 1:41-45.
49. Cleland JGF, Thygesen K, Uretsky EF, Armstrong P, Horowitz JD, Massie B, et al. Cardiovascular critical event pathways for the progression of heart failure: a report from the ATLAS investigators. Eur Heart J 2001; 22:1601-1612.
50. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
51. Bristow MR, Saxon LA, Boehmer J, Kruger S, Kass DA, DeMarco T, Carson P, et al. Cardiac-Resynchronization therapy with or without an implantanle defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150.
52. Klein H, Auricchio A, Reek S, Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HeFT and MADIT-II. Am J Cardiol 1999; 83:91D-97D.
53. Scientific Registry of Transplant Recipients. Available at: http://www.ustransplants.org/index.php.
54. Kubo S, Stevenson L, Miller L, Kobashigawa J, Kenzora J, Torre G, et al. Outcomes in non-urgent patients awaiting transplantation: risk factors for death or deterioration to urgent status [abstract]. J Heart Lung Transplant 1997; 16:42.
55. Bemis CE, Gorlin R, Kemp HG, Herman MV. Progression of coronary artery disease: a clinical arteriographic study. Circulation 1973; XLVII:455-464.
56. Lichtlen P, Nikutta P, Jost S, Deckers J, Wiese B, Raffleneul W and the INTACT Study Group. Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitated coronary angiography: relation to clinical events and risk factors. Circulation 1992; 86:828-838.
57. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Liang YK, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82:1940-1953.
58. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993; 87:1067-1075.
59. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, et al. Progression of coronary artery disease predicts clinical coronary events: Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996; 93:34-41.
60. Bruschke AVG, Kramer JR, Bal ET, Ul Haque I, Detrano RC, Goormastic M. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arterioraphy three times. Am Heart J 1983; 117:296-305.
61. Moise A, Theroux P, Taeymans Y, Waters DD, Lesperance J, Fines P, et al. Clinical and angiographic factors associated with progression of coronary artery disease. J Am Coll Cardiol 1985; 5:659-667.
62. Yokoya K, Takatsu H, Suzuki T, Hosokawa H, Ojio S, Matsubara T, et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: a study based on four serial coronary arteriograms per year. Circulation 1999; 100:903-909.
63. Buchwald H, Matts JP, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, et al., for the Program on the Surgical Control on the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992; 268:1429-1433.
64. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89:975-990.
65. Niebauer J, Hambrecht R, Velich T, Hauer K, Marburger C, Kalberer B, et al. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation 1997; 96:2534-2541.
66. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
67. Hedrich O, Jacob MC, Gavard JA, Hauptman PJ. Progression of coronary artery disease in non-ischemic dilated cardiomyopathy: an under-estimated phenomenon? J Card Fail 2003; 9:S99.
68. Leape LL, Hilborne LH, Kahan JP, Stason WB, Park RE, Kamberg CJ, et al. Coronary artery bypass graft: a literature review and ratings of appropriateness and necessity. Publication JRA-02. Santa Monica: RAND Corporation; 1991.
69. Anker SD, Clark AL, Kilkowski C, Zugck C, Cicoira M, Ponikowski P, et al. Stalins and survival in 2068 CHF patients with ischemic and non-ischemic etiology. Circulation 2002; 106(suppl):II-513.
70. Horwich TB, MacLellan R, Fonarow GC. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol 2004; 43:642-648.
71. Ashton E, Liew D, Krum H. Should patients with chronic heart failure be treated with 'statins'? Heart Fail Mon 2003; 3:82-86.
72. Horwich TB, Hamilton MA, MacLellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8:216-224.
73. The National Cholesterol Education Program (NCEP) Expert Panel. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda: National Heart, Lung, and Blood Institute, National Cholesterol Education Program; September 2002. NIH Publication No. 02-5212.
74. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
75. Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch Int Med 2003; 163:1574-1579.
76. Teo KK, Yusuf S, Pfeffer M, Kober L, Hall A, Pogue J, et al. ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360:1037-1043.
77. Teerlink JR, Massie BM. The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers. Am Heart J 1999; 138:193-197.
78. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41:62S-69S.
79. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347:969-974.